Abstract

Introduction: The term "metabolic syndrome" (MetS) refers to a group of symptoms that can include elevated blood pressure, hyperglycemia, excess body fat around the waist, and abnormal cholesterol levels. These conditions can occur in combination and increase the risk of heart disease, stroke, diabetes, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). An estimated 34% of adults in the United States have MetS, according to the Third National Health and Nutrition Examination Survey. The present study is aimed to assess liver enzymes aspartate transaminase, alanine transaminase, gamma glutamyl transaminase and alkaline phosphatase in patients with metabolic syndrome and healthy controls. Results: In the present study it is found that the mean age of the patients were 41.4 ± 10.4 years in healthy controls and 42.9 ± 9.8 years in MetS group. Out of 50 healthy controls 34 were males and 16 were females and in MetS group 36 were males and 14 were females. There were 64% current smokers, 16% ever smokers and 10% never smoked in healthy and in MetS group 64% were current smokers, 16% ever smokers and 20% never smokers as presented in Table 1. The mean levels of SBP, DBP, Fasting plasma glucose, alanine transaminase, aspartate transaminase, gamma glutamyl transferase and alanine transaminase were elevated in MetS group as compared to healthy controls and the elevation was statistically highly significant. Conclusion: In conclusion, our determined that the liver enzyme levels are indeed associated with the MetS risk, both in overall populations and in subjects with liver enzymes within-normal-limits. The assessment of liver enzymes can be used a clinical predictors of MetS.

Description